Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson's Disease.

Grealish, Shane; Diguet, Elsa; Kirkeby, Agnete; Mattsson, Bengt; Heuer, Andreas; Bramoulle, Yann; Van Camp, Nadja; Perrier, Anselme L; Hantraye, Philippe; Björklund, Anders; Parmar, Malin

Published in:
Cell Stem Cell

DOI:
10.1016/j.stem.2014.09.017

2014

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease

Highlights

Transplants of hESC-DA survive long term and restore DA neurotransmission in vivo

The functional potency of hESC-DA is similar to human fetal midbrain DA neurons

hESC-DA are capable of long-distance, target-specific innervation of the host brain

The axonal outgrowth capacity of hESC-DA meets the requirements for use in humans

Authors

Shane Grealish, Elsa Diguet, ..., Anders Björklund, Malin Parmar

Correspondence

shane.grealish@med.lu.se (S.G.), malin.parmar@med.lu.se (M.P.)

In Brief

Grealish et al. provide preclinical evidence that hESC-derived dopamine neurons are functionally equivalent to those derived from fetal tissue, supporting continued development of hESC-derived cells as a clinical approach for the treatment of Parkinson’s disease.
Clinical Progress

Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease

Shane Grealish, Elsa Diguet, Agnete Kirkeby, Bengt Mattsson, Andreas Heuer, Yann Bramoulle, Nadja Van Camp, Anselme L. Perrier, Philippe Hantraye, Anders Björklund, and Malin Parmar

INTRODUCTION

Cell replacement therapy in Parkinson’s disease (PD) is based on the premise that transplanted midbrain dopamine (DA) neurons can restore dopaminergic neurotransmission when transplanted to the DA-depleted striatum, providing a functionally efficient substitute for the neurons that are lost in the disease. Clinical trials using cells derived from human fetal ventral mesencephalon (VM) have shown that transplanted DA neurons can functionally reinnervate the denervated striatum, restore DA release, and at least in some PD patients, provide substantial long-term clinical improvement (Barker et al., 2013; Kefalopoulou et al., 2014). However, the use of tissue from aborted human embryos presents several ethical and logistical issues that hamper the effective translation of fetal tissue transplantation as a realistic therapeutic option.

In order to move to large-scale clinical applications, a readily available, renewable, and bankable source of cells with the potential to differentiate into fully functional DA neurons after transplantation is an absolute requirement. Among the different stem cell sources available, human pluripotent stem cells, in particular human embryonic stem cells (hESCs), have advanced the furthest (Lindvall and Kokaia, 2009; Barker, 2014). Using protocols entirely based on extrinsic patterning cues that mimic fetal midbrain development, it is now possible to generate DA neurons with an authentic midbrain phenotype from human pluripotent stem cells that survive transplantation and that can restore motor deficits in animal models of PD (Doi et al., 2014; Kirkeby et al., 2012a; Kriks et al., 2011).

However, a number of crucial issues need to be addressed in preclinical studies before these cells can be considered for clinical use: it is important to verify that their functional efficacy is robust, reproducible, and stable over significant time periods; that the transplanted cells have the capacity to grow axons and reinnervate the DA-denervated host striatum over distances that are relevant for the size of the human brain; and that they function with equal potency to human fetal VM DA neurons that have previously been used in clinical trials (Barker, 2014).

Here we have performed a rigorous preclinical assessment of long-term in vivo functionality and axonal outgrowth capacity of hESC-derived midbrain DA neurons, critical for their translation to the clinic. We show long-term survival and functionality using clinically relevant MRI and positron emission tomography (PET) imaging techniques and efficacy in restoration of motor function that is comparable to that seen with human fetal cells. Importantly, we provide a direct comparison of human DA neurons sourced from either hESCs or fetal VM and show that hESC-derived neurons, like their fetal counterparts, can project over long distances in the lesioned adult rodent brain and regenerate axonal projections with cell-type specific innervation of correct target structures.

SUMMARY

Considerable progress has been made in generating fully functional and transplantable dopamine neurons from human embryonic stem cells (hESCs). Before these cells can be used for cell replacement therapy in Parkinson’s disease (PD), it is important to verify their functional properties and efficacy in animal models. Here we provide a comprehensive preclinical assessment of hESC-derived midbrain dopamine neurons in a rat model of PD. We show long-term survival and functionality using clinically relevant MRI and PET imaging techniques and demonstrate efficacy in restoration of motor function with a potency comparable to that seen with human fetal dopamine neurons. Furthermore, we show that hESC-derived dopamine neurons can project sufficiently long distances for use in humans, fully regenerate midbrain-to-forebrain projections, and innervate correct target structures. This provides strong preclinical support for clinical translation of hESC-derived dopamine neurons using approaches similar to those established with fetal cells for the treatment of Parkinson’s disease.
target structures. These data represent an important milestone in the preclinical assessment of hESC-derived DA neurons and provide essential support for their usefulness in cell replacement therapy for PD.

RESULTS

Long-Term Survival and Restoration of Dopaminergic Neurotransmission by hESC-DA Neurons

First, we wanted to assess long-term survival and function of grafted cells using methodologies that are used in the clinic. We therefore transplanted hESC-derived DA (hESC-DA) neurons to the striatum of 6-hydroxypamin (6-OHDA)-lesioned athymic, adult rats, allowing for long-term graft survival in the absence of immunosuppressive treatment. The grafted animals were followed up to 6 months after transplantation, the point at which grafts of fetal VM in patients start to become functional (Piccini et al., 2000). T2-weighted MRI imaging showed surviving transplants that increased in volume from 1 to 5 months post-transplantation, indicating initial proliferation and subsequent maturation of the transplanted cells (Figures S1A available online), as previously described for transplants of proliferative midbrain progenitors (Kirkeby et al., 2012a). MR spectroscopy investigation 5 months postgrafting revealed a high N-acetylaspartic acid content within the transplanted area, indicative of a neuron-rich graft (Figures S1B and S1C). Pretransplantation, the rats were assessed for deficits in striatal dopaminergic neurotransmission by PET, using 18F-fallypride as a tracer for the dopamine transporter (DAT) (Dolle et al., 2010), and 18F-LBT999 as a tracer for the dopamine transporter (DAT) (Dolle et al., 2007) (Figure 1A). In the 6-OHDA-lesioned DA-denervated striatum, 18F-fallypride binding was significantly increased, as compared with the intact hemisphere, indicating a pronounced reduction in DA release. After grafting, 18F-fallypride binding was normalized to intact levels as assessed 5 months posttransplantation, indicative of active DA release from the transplanted hESC-DA neurons (Figures 1A and 1B). Similarly, the near-complete loss of DAT binding, using 18F-LBT999, seen after 6-OHDA lesion was reversed to around 50% of normal (Figures 1A and 1C). 18F-DPA714 binding was used to measure microglial activation (Kuhnast et al., 2012), and no increase was observed at 5 months postgrafting, relative to the nontransplanted side (Figure 1A).

Histological Analysis and Innervation Capacity of hESC-DA Neurons after Intrastratal Transplantation

Histological analysis confirmed the imaging data, showing neuron-rich transplants and revealing grafts rich in DA neurons, expressing both tyrosine hydroxylase (TH) and dopamine transporter (DAT), in the absence of a notable active microglial (Iba1+) response, overgrowths, or necrotic areas (Figures S2A–S2C). To assess graft-derived axonal outgrowth we made use of an antibody specific for human neural cell adhesion molecule (hNCAM) (Figures 1D–1G), allowing selective and highly sensitive visualization of the grafted neurons and their projections. Dense hNCAM+ innervation was observed throughout the caudate-putamen, including the dorsolateral striatum, which derives its innervation exclusively from the A9 neurons of the substantia nigra (SN) (Figure 1D). Similar innervation was also observed in other forebrain DA target areas outside the caudate-putamen, such as nucleus accumbens (NAc) (Figure 1E), olfactory tubercle (Figure 1D), and the perirhinal and prelimbic cortices (Figures 1F and 1G), which are essential targets for the A10 neuronal subtype, residing in the ventral tegmental area (VTA) (Figures S2D and S2E).

Taken together, these data prove the ability of hESC-DA neurons to provide extensive reinnervation of the host striatum and begin to restore DAergic neurotransmission 5 months posttransplantation, using clinically relevant methods to assess graft function, in the absence of significant adverse events. This is in line with previous clinical observations using human fetal VM grafted to patients, where progressive recovery of DA neurotransmission starts at 6 months, reflecting the gradual maturation of the transplanted cells (Piccini et al., 1999, 2000).

Functional Potency Assessment of hESC-DA Neurons Grafted to the Striatum

We and others have previously shown that hESC-DA neurons can release DA in vivo (Kirkeby et al., 2012a) and restore a number of motor deficits in 6-OHDA rodent models of PD when assessed 16–18 weeks after grafting (Kirkeby et al., 2012a; Kriks et al., 2011). However, these transplants contained 15,000–18,000 hESC-derived DA neurons, and the high cell number makes it difficult to estimate the efficacy of the cells (Barker, 2014). In previous preclinical and experimental studies using grafts of human fetal VM, it has been shown that normalization of amphetamine-induced rotation after intrastrial transplantation can be achieved with an average number of 1,200 surviving TH+ neurons (Brundin et al., 1986). On the basis of this information, we performed a potency experiment designed to determine the minimal number of hESC-DA neurons capable of inducing functional recovery in the amphetamine-induced rotation test. We transplanted 6-OHDA lesioned rats, aiming for at least a 10-fold lower number of hESC-DA than the grafts functionally assessed in earlier studies (Kirkeby et al., 2012a; Kriks et al., 2011). The rats were pretested to confirm the completeness of the lesion and immunosuppressed with daily injections of ciclosporin for 18 weeks. At this time point, the rats showed a significant recovery in amphetamine-induced rotation (Figure 2A: \( t_4 = 6.76, p < 0.01; n = 5 \)), despite a much lower number of TH+ neurons in the grafts (Figures 2B and 2C). Quantifications showed that the average number of surviving TH+ neurons was 986 ± 333 per rat (\( n = 5 \)). Two of the rats had less than 500 surviving hESC-DA neurons and yet showed a complete reduction in rotational bias (Figure 2B). Within TRANSERUO, a EU-funded research consortium formed to develop an efficacious and safe treatment methodology for PD using fetal cell based treatments (http://www.transneuro.org.uk), research groups including our own have optimized and standardized tissue preparation protocols across several centers throughout Europe. A recent report with cells prepared using this protocol show that a significant reduction in amphetamine-induced rotation could be achieved with transplants of human fetal VM with as few 657 ± 199 surviving TH+ neurons (Rath et al., 2013). These results indicate that the functional potency of grafted hESC-DA neurons is on par with that of human DA neurons obtained from fetal VM (Brundin et al., 1986; Rath et al., 2013).
**Figure 1. Functional Imaging of Long-Term Surviving Intrastriatal Transplants of hESC-DA Neurons**

(A) MRI and PET scans for 18F-fallypride, 18F-LBT999 after 6-OHDA lesion, show an increase in binding of 18F-fallypride (n = 6) on the side of lesion indicating an impaired DA release, confirmed by a loss of 18F-LBT999 (n = 7) binding due to loss of DAT binding sites. At 5 months posttransplantation both 18F-fallypride (n = 11) and 18F-LBT999 (n = 14) binding are restored toward normal, indicative of a graft rich in functional DA neurons, in the absence of any detectable microglial response, as assessed with 18F-DPA714 (n = 13).

(B) Quantitative measurements of binding ratios between intact and lesioned striatum revealed an increased binding potential of 18F-fallypride in the 6-OHDA denervated striatum, which was normalized to intact levels 5 months posttransplantation of hESC-DA neurons.

(C) A 6-OHDA lesion resulted in a near complete loss of 18F-LBT999 binding due to the loss of DAT-expressing dopaminergic terminals, which was restored toward normal posttransplantation.

(D and E) Immunohistochemistry of hNCAM revealed neuron-rich grafts of hESC-DA neurons 6 months posttransplantation, providing extensive innervation of the host CPu and surrounding extrastriatal dopaminergic targets, such as NAc.

(F and G) Away from the graft core, widespread innervation by human axons was found in known DA target structures within the prefrontal cortex.

See also Figure S1: AC, anterior commissure; CPu, caudate-putamen unit; FM, forceps minor; NAc, nucleus accumbens; PrL, prelimbic cortex; T, transplant. In (B) and (C), data are represented as mean ± SEM. *p < 0.01. In (A), (D), and (F), scale bars represent 1 mm. In (E) and (G), scale bars represent 0.5 mm.
Histological Comparison of DA Neurons Sourced from Human Fetal VM and hESCs after Intrastriatal Transplantation

We next performed a direct histological comparison between hESC-DA neurons and authentic human fetal DA neurons prepared according to Rath et al. (2013), grafted in parallel, in order to validate the morphology, maturation, and phenotypic properties of the transplanted DA neurons (Figures 2D and 2E). In this analysis, we observed the presence of TH\(^+\) neurons with two distinct morphologies in the hESC-grafted animals (Mendez et al., 2005; Thompson et al., 2005): A9-like nigral neurons characterized by large angular somata and A10-like VTA neurons with small, round somata (Figure 3A). The morphology of the hESC-derived neurons was identical to that observed with intrastriatal transplants of fetal VM when analyzed at 6 months posttransplantation (Figure 3C) and consistent with graft appearance from previous postmortem reports from transplanted PD patients (Mendez et al., 2005). When staining the cells for markers commonly used to distinguish between SN (A9) and VTA (A10) neurons, TH\(^+\) neurons expressing GIRK2 (A9), Calbindin (A10), or both markers were readily detected (Figures 3B and 3D). Quantifications showed that TH\(^+\)/GIRK2\(^+\) neurons were the most abundant subtype in both hESC-derived and fetal grafts (Figure 3I) and that the proportion was similar in both hESC- and fetal-derived grafts (Figure 3J). Taken together, this analysis shows that hESC-DA neurons are indistinguishable from their fetal counterparts on the basis of graft appearance, morphology, and marker expression 6 months after grafting and that the hESC-derived grafts are rich in both A9-like and A10-like DA neurons.

Long-Distance Axonal Outgrowth of hESC-Derived Neurons after Transplantation into the Substantia Nigra

When assessing the cells for their suitability to be used in clinical trials, it is important to keep in mind that the human brain is a much larger structure than the rodent brain and that it is necessary for the transplanted cells to extend axons over long distances in order to sufficiently reinnervate the putamen in patients. We therefore sought to create an assay through which long-distance, target-specific outgrowth could be assessed in an adult rodent model of PD that would be predictive when translating to the larger human brain. Intrastriatal grafting, the standard used in preclinical and clinical studies, places the cells within their main target structure, thus making it difficult to assess the full innervation capacity of human cells when grafted to the rat brain. To investigate the ability of hESC-DA neurons to innervate specific structures across longer distances, we employed a homotopic grafting approach where we transplanted hESC-DA neurons into the lesioned SN, instead of the traditional ectopic transplantation in the striatum. Transplants of fetal VM served as an important reference to see if hESC-derived neurons could match their capacity for long-distance and target-specific innervation.

When grafted to the SN, both hESCs and fetal VM gave rise to grafts rich in TH\(^+\) neurons expressing GIRK2 and Calbindin with morphologies indistinguishable from cells grafted to the striatum (compare Figures 3E–3H with Figures 3A–3D). In the majority of rats with fetal VM transplants (n = 7/8), we observed neuron-rich grafts, discretely placed within the host SN, extending large numbers of hNCAM\(^+\) axons rostral along the medial forebrain bundle (MFB) and the adjacent nigrostriatal pathway, assembled in a well-defined and fasciculated tract (Figures 4A, 4G, 4I, S3A, and S3B). Rostral extending axonal bundles were seen to defasciculate and ramify within their terminal target fields, providing widespread innervation of specific host structures throughout the forebrain (Figure 4A), extending more than 10 mm from the graft core. hNCAM\(^+\) terminal innervation was particularly dense in caudate-putamen (Figure 4C), NAc (Figure 4D), amygdala (Figure 4B), and perirhinal and anteromedial frontal cortices (Figures 4A and 4E).
Upon close inspection, hESC-DA neurons gave rise to TH⁺ dopaminergic neurons in Long-Term Grafts of hESC-DA Neurons and Human Fetal VM (Figure 3). Comparison of A9 and A10 Midbrain DA Neuron Subtypes, TH and Calbindin (red and blue) indicates that both midbrain DA neuron subtypes, A9 and A10, were contained in grafts of hESC-derived neurons.

In (B), TH/GIRK2 (red and green) and TH/Calbindin (red and blue) coexpressing dopaminergic neurons are observed. Notably, graft-derived hNCAM⁺ glial cells were detected in the transplants derived from the 8-week-old fetus (Figures 4F and 4G), but not from the younger 5.5-week-old fetus (Figures 4H and 4I). In the grafts of 8-week fetal VM, the graft-derived glial cells could be traced along myelinated and nonmyelinated fiber tracts, accompanying the hNCAM⁺ axons up to the level of the caudal caudate-putamen (Figure 4G), as described in previous xenografting studies (Gates et al., 1998; Isacson et al., 1995; Pundt et al., 1995). Despite the absence of graft-derived glia in the transplants of the younger embryo (Figure 4H), hNCAM⁺ fiber outgrowth was comparable to grafts derived from older tissue (Figures S3B–S3G). This observation indicates that the extent and patterning of axonal outgrowth is largely independent of this glial population present within the transplant.

Six months posttransplantation we observed robust survival in all hESC grafted animals (n = 8/8), with no signs of overgrowth or necrosis, similar in morphology to the intrastriatal grafts of hESC-DA neurons described above (Figures 1, 2D, and S2A–S2C). As observed with intranigral transplants of fetal VM, large numbers of hNCAM⁺ fibers projected rostral along the MFB and the adjacent nigrostriatal pathway (Figures 5A, 5F, S4A, and S4B). The axons extending along the MFB continued a distance more than 10 mm from the graft core and gave rise to dense terminal networks in amygdala (Figure 5B); dorsolateral striatum (Figure 5C) and piriform cortex; ventral striatum, including NAc (Figure 5D); olfactory tubercle; lateral septum; and large parts of the frontal lobe (Figures 5A, 5E, and 5G). hNCAM⁺ cells with a glial morphology were not detected in any of the hESC-grafted rats, consistent with our hypothesis that they are not essential for extensive axonal outgrowth.

**Subtype Identity and Target-Specific Innervation of hESC-DA Neurons after Transplantation into the Substantia Nigra**

Although A9 and A10 midbrain DA neuron subtypes can be arbitrarily distinguished on the basis of morphology and GIRK2/Calbindin protein expression, true identification of the subtype is linked to the ability of the neurons to innervate their appropriate forebrain targets: the A9 preferentially innervating the caudate-putamen and A10 neurons innervating limbic and cortical areas, including ventral striatum and NAc. To determine the presence of authentic A9 or A10 subtypes in grafts of fetal VM and hESC-DA neurons, we performed quantitative fiber density measurements (Figures S5A and S5B) of human hNCAM⁺ axons (Figure 6C) in (C and D) Intrastriatal grafts of human fetal VM contained TH⁺ dopaminergic neurons with A9 and A10 morphologies, coexpressing GIRK2 and/or Calbindin. (E and F) Homotopic placement of hESC-DA neurons, coexpressing GIRK2 and/or Calbindin, respectively. (G and H) Fetal VM tissue grafted to the SN displayed the same ability to generate transplants with dopaminergic neurons of A9 and A10 morphologies and protein expression (H).

![Figure 3. Comparison of A9 and A10 Midbrain DA Neuron Subtypes in Long-Term Grafts of hESC-DA Neurons and Human Fetal VM](image-url)

- **A** Upon close inspection, hESC-DA neurons gave rise to TH⁺ dopaminergic neurons with an A9-like neuron morphology, characterized by large angular somas (upper panel), as well as A10-like neurons with small, round somas (lower panel).
- **B** The presence of neurons coexpressing TH and GIRK2 (red and green) and TH and Calbindin (red and blue) indicates that both midbrain DA neuron subtypes, A9 and A10, were contained in grafts of hESC-derived neurons.
defined striatal areas (A9 targets), as well as limbic and cortical areas (A10 targets), as depicted in Figure S5C. We found that the number of axons projecting rostral was similar in the VM (2,169 ± 181; n = 3) and hESC (2,453 ± 774; n = 4) groups. Overall, the fiber density measurements showed that the midbrain-patterned hESCs exhibited the same A9/A10 target specificity and axonal outgrowth patterns as human fetal VM cells. Both fetal VM- and hESC-derived neurons innervated the caudate-pu
tamen, which in the rat is targeted almost exclusively by A9 neurons, but that fetal VM tissue was more efficient at innervating the dorsolateral caudate-putamen (Figure 6A: dorsomedial, t25 = 2.69, p < 0.01; dorsolateral, t25 = 4.38, p < 0.0001; Medial, t25 = 2.14, p < 0.05). All A10-specific target structures were innervated at similar densities by fetal VM and hESCs, with the exception of the infralimbic cortex and septum, which received a more pronounced innervation from the hESC grafts (Figure 6B: ILC, t25 = 5.99, p < 0.0001; Sept, t25 = 5.32, p < 0.0001).

In order to identify the specific contribution from grafted DA neurons, we utilized immunofluorescence to detect human axons coexpressing TH and hNCAM (Figure 6F). Performing fiber density counts on double-positive fibers; we again found that fetal- and hESC-derived DA neurons demonstrated a similar propensity to innervate A9 and A10 specific striatal target structures (Figures 6D and 6E), although A9-specific innervation derived from fetal VM grafts was overall of higher density (Figure 6D: dorsomedial, t4 = 2.27, p < 0.05; dorsolateral, t4 = 4.15, p < 0.01).

In summary, midbrain-patterned hESCs exhibited the same remarkable ability as their fetal counterparts to extend axons over long distances and provide specific innervation of the relevant A9 and A10 host target structures. GIRK2 and Calbindin are commonly used as subtype markers for stem cell-derived DA neurons in vitro and after transplantation (Kirkeby et al., 2012a; Kriks et al., 2011; Ryan et al., 2013). However, we notice here that a high GIRK2+ component (Figures 3I and 3J) does not directly translate to a strong innervation of the A9 target structures (Figures 6A and 6D). This observation is supported by the postmortem analysis of the adult human midbrain, which reveals that colocalization of TH and GIRK2 occurs in all DAergic neurons of the SN, but also an additional portion of DAergic neurons of the VTA (Reyes et al., 2012), thus calling for a more stringent analysis of A9 subtype of stem cell-derived DA neurons.

Expression of OTX2 Alters the Axonal Outgrowth Pattern of Transplants of hESC-Derived Neurons

Next, we sought to investigate if target-specific axonal outgrowth from hESC-DA neurons that can be regulated by transcriptional programming. Experiments in mice have established a major role for the transcription factor Otx2 in the development of the midbrain DA progenitors. The expression of this transcription factor is maintained selectively in DA neurons with a mature A10 phenotype, where it acts to control the pattern of axonal outgrowth in forebrain structures (Chung et al., 2010, 2005; Di Salvio et al., 2010a, 2010b). We generated transgenic hESCs (OTX2-
hESCs) using a lentiviral construct that expresses OTX2 at physiologically relevant levels under the control of the PGK promoter and contains miRNA-292 target sequences to restrict expression to differentiated progeny (Sachdeva et al., 2010) (Figures S6A and S6B). We verified that the transgene did not disturb patterned toward a midbrain fate, as OTX2-hESCs gave rise to a similar number of LMX1A, FOXA2, and OTX2 expressing progenitors, as compared with wild-type (WT) hESCs (compare Figures S6D and S6E with Figures S4C and S4D). At a later time point in vitro, and consistent with the emergence of mature TH+ neurons, OTX2 was downregulated in mature MAP2+/TH+ neurons from parental WT hESCs, but specifically maintained in differentiated OTX2-
hESCs (Figures S6C and S6F). The OTX2-hESC-derived DA neuron progenitors were transplanted to the SN of 6-OHDA-lesioned athymic rats (n = 8). At 6 months, immunohistochemical analysis revealed a pronounced expression of OTX2 within the graft core at a level exceeding that observed in grafts of fetal VM and WT hESCs (Figures S6G–S6I). The OTX2-hESC grafts exhibited a similar axonal outgrowth pattern to the WT hESCs, with large numbers of hNCAM+ axons extending rostral within the MFB (Figures 7A and 7B). However, the innervation derived from the OTX2-hESCs was restricted almost exclusively to A10 target structures, including NAc; ventral striatum; septum; amygdala; and antero-medial regions of the prefrontal cortex (Figures 7A–7E and S6K). Few, if any, hNCAM+ fibers were observed in A9 target structures, such as dorsolateral caudate-putamen (Figures 7A and 7C). When quantifying the innervation of all measured A9 structures (dorsomedial, dorsolateral, medial, and central aspects of the caudate-putamen unit; Figure S5C), OTX2-hESCs displayed a reduced preference for innervating A9 target structures both when compared with grafts of the parental hESCs and with fetal-derived DA neurons (Figure 7H: F(2, 105) = 28.91, p < 0.0001; difference confirmed using a Tukey’s post hoc test, p < 0.001).

To exclude that this dramatic switch in target innervation was due to experimental variation or altered in vitro patterning, we replicated this experiment with a new cell differentiation and transplanted to immunocompetent rats under immunosuppression.
using daily injections of ciclosporin. In all animals (n = 7/7; 14-week survival), grafts of OTX2-hESCs were efficiently differentiated into mature TH+ neurons (Figure S6 J), and the identical pattern of A10-specific target innervation was observed (Figures 7F and 7G).

These findings provide evidence that target-specific outgrowth, attributed to a given midbrain DA neuron subtype, can be controlled and redirected in hESC-derived cell preparations, thus providing an opening for future efforts to enhance the fiber outgrowth to specific target nuclei.
In this study, we have performed a comprehensive preclinical validation of hESC-derived DA neurons that fully supports their functional efficacy and capacity for long-distance, target-specific reinervation, predictive of their therapeutic potential.

Using imaging techniques previously used to assess graft function in patients (Kefalopoulou et al., 2014; Piccini et al., 1999), we demonstrate that hESC-DA neurons survive, mature, and restore DA neurotransmission in the denervated striatum for up to 6 months postgrafting. When compared side-by-side with their fetal counterparts, the hESC-DA neurons appear identical in terms of morphology and marker expression, supporting their authenticity and stable phenotype. Importantly, we have also performed an equipotency assay, establishing that the hESC-DA neurons can completely reverse motor asymmetry in the drug-induced rotation test in numbers more than 10-fold lower than previously used (Kirkeby et al., 2012a; Kriks et al., 2011) and at a dose, i.e., a threshold number, of around 1,000 surviving DA neurons, similar to that seen with human fetal VM tissue (Brundin et al., 1986; Rath et al., 2013). Knowing that the number of surviving fetal DA neurons in a transplanted patient needs to be at least 100,000 in order to achieve a good clinical outcome (Hagell and Brundin, 2001), the equipotency data presented here will be important for guiding cell dosage when designing the first-in-man trial with hESCs.

We show that midbrain-patterned hESCs transplanted homotopically to the SN exhibit the same remarkable ability as their fetal counterparts to project axons over long distances in the adult brain, providing highly specific and appropriate innervation of midbrain DA target structures in the forebrain (Isacson et al., 1995; Victorin et al., 1992). Intriguingly, and of clinical importance, this extensive axonal outgrowth occurs in the adult brain. While other reports have previously described long-distance outgrowth from transplants of hESC-derived neurons, these studies have been performed in neonatal rats and mice (Denham et al., 2012; Espuny-Camacho et al., 2013) and have not used hESCs patterned toward a specific dopaminergic fate. The capacity of the hESC-DA neurons to reinervate previously denervated forebrain targets when transplanted to the SN is unparalleled and matched well the axonal outgrowth patterns obtained from grafts of authentic human fetal midbrain DA neurons.

Clinical studies show that grafts of fetal VM-derived DA neurons, transplanted to the DA-deficient putamen, can restore DA neurotransmission and provide functional benefits that are sustained over many years (Barker et al., 2013; Kefalopoulou et al., 2014). From preclinical studies we know that the efficacy of intrastralial DA neuron grafts depends not only on the number of surviving DA neurons but also on their phenotype and their capacity to reinervate a major part of the denervated target. We show here that the hESC-DA neurons generated by the current protocol are of the correct midbrain phenotype and contain the two major A9 and A10 DA neuron subtypes, similar to fetal VM grafts. This phenotype provides the grafts with the capacity to reinervate both striatal and extrastriatal midbrain DAergic target structures. Importantly, we show that hESC-DA neurons are functionally equipotent to fetal VM neurons when grafted to the striatum and their axonal growth capacity matches that achieved by fetal VM neurons when grafted to the striatum and the SN. Data from transplantation studies in rodents and human autopsy cases indicate that DA neurons from human fetal VM have the capacity to extend axons for up to 5–7 mm in the...
Figure 7. Maintained Expression of OTX2 in hESC-Derived Neurons Results in an Altered Axonal Outgrowth Pattern

(A) Schematic overview of the pattern of hNCAM+ axonal outgrowth derived from intranigral grafts of OTX2-hESCs 6 months posttransplantation, as visualized under dark-field illumination of DAB-developed sections (see Figure S6K). These cells displayed a strong preference for A10 target structures, such as septum, cingulate, prelimbic, and infralimbic cortices.

(B) The majority of axons extended rostral within the MFB, along both gray and white matter, with few axons innervating amygdala.

(C) Only rare hNCAM+ axons were observed in caudate-putamen, the prime A9 target structure.

(D and E) Maintained expression of OTX2 did not alter the long-distance growth capacity of the grafted neurons, as a dense fiber network was observed in both septum and NAc, as well as in prelimbic cortex.

(legend continued on next page)
striatum, which makes it possible to reinnervate a major part of the human putamen with a limited number of cell deposits (Freeman and Brundin, 2006; Kordower et al., 1995). The axonal outgrowth observed here, up to 10 mm from the graft deposit, indicates that the growth capacity of the hESC-derived DA neurons will be sufficient to provide efficient and widespread restoration of DA neurotransmission in the DA-denervated striatal targets in PD patients. The potency of the hESC-derived DA neurons, with respect to functional efficacy and long-distance targeted reinnervation, is on par with that of fetal VM cells, which provides important support for their therapeutic potential and use for cell replacement therapy in PD.

**EXPERIMENTAL PROCEDURES**

**Research Animals**

All procedures were conducted in accordance with the European Union Directive (2010/63/EU) and were approved by the ethical committee for the use of laboratory animals at Lund University and the Swedish Department of Agriculture (Jordbruksverket), as well as French legislation.

Athymic, nude rats were housed in individual ventilated cages, under a 12 hr light/dark cycle with ad libitum access to sterile food and water. Sprague-Dawley rats were kept in similar conditions as above, but in standard cages.

**Experimental Design for Functional Imaging Experiment**

Adult (~1 year) male, athymic, nude rats (Crl:NH-Foxn1Ncr) were purchased from Charles River and used as graft recipients in all experiments and controls (n = 20). All rats received a 6-hydroxydopamine lesion of the medial forebrain bundle and 2 weeks later were assessed for lesion efficacy using amphetamine-induced rotations. All animals received longitudinal follow using MRI. The animals were stratified to the follow groups: baseline PET scanning, with subsequent follow-up scans at 5 to 6 months posttransplantation (n = 14), and MR spectroscopy of the grafts (n = 9).

**Experimental Design for Circuit Reconstruction and Equipotency Experiments**

Adult (~180 g) female, athymic, nude rats (Hsd:RnH-Foxn1Ncr) were purchased from Harlan Laboratories and used as graft recipients and controls (n = 51). For repetition of the OTX2-overexpression and equipotency experiments, female Sprague-Dawley rats (225–250 g) were purchased from Charles River (n = 14 and n = 5, respectively) for all surgical procedures. Additional details are provided in the Supplemental Experimental Procedures.

**Amphetamine-Induced Rotation**

Rotational bias, after systemic amphetamine challenge (2.5 mg/kg, intraperitoneally; Apoteksbolaget), was recorded using an automated system (Omnitech Electronics). The animals were recorded for 90 min, and only full body turns were counted and then expressed as net turns per minute, with rotations toward the side of the lesion given a positive value. Only animals with more than 5 turns per minute were considered successfully lesioned.

**Differentiation of hESCs**

Human ESCs H9 (WA09, passages 31–45) were differentiated to a ventral midbrain fate, using the protocol as described in detail in Kirkeby et al. (2012b) and Supplemental Experimental Procedures.

**Human Fetal Tissue**

Human fetal tissue was obtained from legally terminated embryos with approval of the Swedish National Board of Health and Welfare in accordance with existing guidelines including informed consent from women seeking elective abortions. The gestational age of each embryo was determined by measuring the crown-to-rump length and/or estimated by ultrasound measurements. Embryos were then staged according to weeks postconception.

**Transplantation Procedure**

hESCs were prepared for transplantation as in Kirkeby et al. (2012a), while fetal tissue was prepared and transplanted as a semicrude suspension, as described in Rath et al. (2013).

**Magnetic Resonance and PET Imaging**

All specifications of these procedures are detailed in Supplemental Experimental Procedures.

**Immunohistochemistry**

All samples, cultured cells and brain tissue, were fixed in fresh 4% paraformaldehyde. A complete list of suppliers and concentrations of primary and secondary antibodies used is detailed in Supplemental Experimental Procedures.

**Fiber Density Measurements**

Quantitative analysis of the density of human fibers innervating specific areas was performed using a stereological method (Mouton et al., 2002). Details of sampling and acquisition are described in Supplemental Experimental Procedures.

**Statistical Analysis**

All data are presented as mean ± SEM. Statistical tests and biological replicates are stated in results or in the figure legends. All statistical analyses were performed using GraphPad Prism v6.0 for Mac OS X. An alpha level of p < 0.05 was set as a threshold for significance.

In Figures 1B and 1C an unpaired t test was used to compare the baseline target areas, such as NAc and septum (F) and prelimbic cortex (G). Notably, this outgrowth pattern was observed as early as 14 weeks after transplantation. In Figures 6A, 6B, and 6D, all fiber density was analyzed using a one-tailed unpaired t test. In Figure 7H the innervation of A9 structures in the OTX2-hESC group was compared with the hESCs and fetal VM grafted groups using a one-way ANOVA, with differences between groups confirmed using a Tukey’s post hoc. The behavioral data in Figure 2A were analyzed with a two-tailed paired t test.

**SUPPLEMENTAL INFORMATION**

Supplemental information includes Supplemental Experimental Procedures and six figures and can be found with this article online at http://dx.doi.org/10.1016/j.stem.2014.09.017.
ACKNOWLEDGMENTS

We would like to thank Jan Reimer, Olle Lindvall, and Jenny Neland¬er-Wahles¬ text for acquisition and processing of human fetal material and Aurore Bugi for preparation and handling of hESC derivatives at I-Stem and Mircen. We would like to recognize the excellent technical assistance provided by Ulla Jarl, Michael Speran¬nini, Anneli Josefsen, and Ingar Nilsson. The excellent technical support of Martine Guiller¬ mie in the PET imaging studies as well as the supply of PET radiol¬gands by the radiochemistry unit of the Service Hospita¬ier Frédéric Jol¬lot (directed by Frédéric Dol¬lé) were very appreciated. This study was supported by grants from the European Community’s 7th Framework Programme through NeuroStemcell (no. 222943), NeuroStemcellRepair (no. 602278), and TransNeo¬ (HEALTH-F5-2010-242003); the strategic research area at Lund University Multipark (multidisciplinary research in Parkinson’s disease); the Swedish Research Council (70862601/Bagadilico, K2012- 99X-22324-01-5, and K2014-61X-20391-08-4); and the Swedish Parkinson Foundation (Parkinsonfonden). S.G. was supported by a postdoctoral stipend from the Swedish Brain Foundation (Hjärnfonden) and A.K. was supported via a grant from the Lundbeck foundation (R44-A3856). The research leading to these results has received funding from the European Research Council under the European Union’s 7th Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 309712.

Received: June 5, 2014
Revised: August 19, 2014
Accepted: September 24, 2014
Published: November 6, 2014

REFERENCES


